CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 32 enrolled
Drug / intervention
Oxaloacetate (OAA) 1g +1 moredrug
Likely dose
Oxaloacetate (OAA) 1gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02593318
NCT02593318Phase 1Completed
CompareCT.gov

Trial of Oxaloacetate in Alzheimer's Disease (TOAD)

Russell Swerdlow·interventional·Posted Nov 2, 2015·Updated Jul 9, 2021

In Brief

A Phase 1 clinical trial evaluating Oxaloacetate (OAA) 1g and Oxaloacetate (OAA) 2g for Alzheimer's Disease (AD). Completed, enrolled 32 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if oxaloacetate (OAA) is safe and tolerable at doses of up to 2 grams per day in people with Alzheimer's disease (AD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease (AD)
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2, 2015
Enrollment StartOct 1, 2015
Primary CompletionSep 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 10.7 years ago

Interventions

Oxaloacetate (OAA) 1gdrug

Pills to be taken orally in 500mg dose two times per day

Oxaloacetate (OAA) 2gdrug

Pills to be taken orally in 1000mg dose two times per day.